Senti Biosciences' (SNTI) Buy Rating Reaffirmed at Chardan Capital

Senti Biosciences (NASDAQ:SNTI - Get Free Report)'s stock had its "buy" rating restated by research analysts at Chardan Capital in a report released on Friday,Benzinga reports. They currently have a $12.00 target price on the stock. Chardan Capital's price objective indicates a potential upside of 277.95% from the stock's current price.

Senti Biosciences Price Performance

Shares of SNTI stock traded down $0.13 during trading hours on Friday, reaching $3.18. The company had a trading volume of 16,857 shares, compared to its average volume of 798,226. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50 day moving average of $3.46 and a 200 day moving average of $3.66. The firm has a market cap of $82.78 million, a price-to-earnings ratio of -0.21 and a beta of 2.31.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.30 million. As a group, sell-side analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Senti Biosciences stock. Virtu Financial LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,356 shares of the company's stock, valued at approximately $47,000. Virtu Financial LLC owned about 0.28% of Senti Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 25.73% of the company's stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.